ClinicalTrials.gg
Active, not recruitingNCT06492291Updated Oct 7, 2025

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

A Phase 3 interventional study of Enlicitide Decanoate in Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 222 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Planned enrollment
2nd of 27
3,000 · median 500
Started
2024
with 1 other
Phase 3
17 of 29
1 open now
Registered
26th of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 17 in phase 3, and was the 26th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed an enlicitide decanoate (also known as enlictide and MK-0616) parent study [MK-0616-013 (NCT05952856), MK-0616-017 (NCT05952869), and MK-0616-018 (NCT06450366)] per protocol (including the final assessments/procedures of their parent study)
  • Had an overall study intervention compliance ≥80% while participating in their parent study

Exclusion criteria

Exclusion Criteria:

  • Has discontinued study intervention in their parent study
  • Has an ongoing serious adverse event considered related to study intervention by the investigator in the parent study
  • Is planning to begin treatment with a nonstudy protein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) while enrolled in the study
  • Is currently participating in an interventional clinical study other than an enlicitide decanoate parent study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    Enlicitide Decanoate

    Participants will receive 20 mg of enlicitide decanoate orally once daily (QD)

    Drug: Enlicitide Decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 3 years

  2. Number of participants who discontinue study drug due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Mean percent change from baseline of the parent study in LDL-C at Week 8 of this extension study

    The percent change from baseline in LDL-C. Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline of the parent study and Week 8 of this extension study

  2. Mean percent change from baseline of the parent study in non-high-density lipoprotein cholesterol (non-HDL-C) at Week 8 of this Extension Study

    The percent change from baseline in Non-HDL-C. Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline of the parent study and Week 8 of this extension study

  3. Mean percent change from baseline of the parent study in apolipoprotein B (ApoB) at Week 8 of this extension study

    The percent change from baseline in apolipoprotein B. Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline of the parent study and Week 8 of this extension study

  4. Percent change from baseline of the parent study in lipoprotein(a) (Lp[a]) at Week 8 of this extension study

    The percent change from baseline in Lp(a). Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline of the parent study and Week 8 of this extension study

  5. Percentage of participants with LDL-C <70 mg/dL and ≥50% reduction from baseline of the parent study

    The percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline at any point during the study. Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline in the parent study and up to approximately 3 years in this extension study

  6. Percentage of participants with LDL-C <55 mg/dL and ≥50% reduction from baseline of the parent study

    The percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline at any point during the study. Each participant's baseline data from their parent study will be used as baseline data for this analysis.

    Time frame: Baseline in the parent study and up to approximately 3 years in this extension study

07

Study locations

222 sites

Showing the first 100 of 222 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Oct 2028, 50 months after the start.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 50 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Oct 13, 2028
CompletionEst.
Oct 13, 2028
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492291
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Aug 5, 2024
Primary completion
Oct 13, 2028 (estimated)
Completion
Oct 13, 2028 (estimated)
Last update
Oct 7, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion